

CLEAN VERSION OF AMENDED CLAIMS - OZ 50761

3. A compound of the formula I as claimed in claim 1, in which

A¹ B can be an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring with a maximum of 15 carbon atoms, an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring with a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms or 0 to 2 sulfur atoms, each of which may also be substituted by a maximum of 3 different or identical R⁵ radicals, and one or two carbon or sulfur atoms may also carry one or two =O groups.

6. A compound of the formula I as claimed in claim 1, in which B is L_v-Y-M_w, where

v is 0, and

w is 1, and

Y is a bond, and

A² M can be a straight-chain or branched carbon chain of 2 to 8 C atoms which contains at least one double bond, it being possible for each carbon atom to be substituted by one or two R⁴ radicals and a maximum of two different or identical R⁵ radicals, and

R¹ is hydrogen, and

R⁴ is D_{0,1}-F_{0,1}-G¹-G²-G³, with G³ equal to hydrogen, and

D is O and NR⁴³, where R⁴³ is hydrogen and C₁-C₃-alkyl and


F¹ is C₂-C₄-alkyl.

7. A drug comprising one or more compounds of the formula I as claimed in claim 1 in addition to conventional carriers and excipients.

CLEAN VERSION OF AMENDED CLAIMS - OZ 50761

- A² 8. The use of compounds of the formula I as claimed in claim 1 or of the formula I where R¹, X¹ and A have the meaning as above, and B can be hydrogen and a C₁-C₆-alkyl chain, for producing drugs with a PARP-inhibiting effect.

-
24. A compound of the formula III



A³ in which

A is a C₁-C₃ chain it being possible for each carbon atom also to carry one or two of the following substituents: C₁-C₄-alkyl, OH, O-C₁-C₄-alkyl, CO₂H, CO₂-C₁-C₄-alkyl and phenyl or one C atom may also carry an =O group, and

X¹ and R¹ have the meanings stated in claim 1,

excluding the compounds

9-amino-3-methyl-1,2,3,4-tetrahydro-5H-1,4-benzodiazepin-5-one,

9-amino-3-methyl-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione,

6,8-diamino-2,4-(1H,3H)-quinazolinedione,

8-amino-2,4-(1H,3H)-quinazolinedione,

and the salts thereof.

MARKED VERSION OF AMENDED CLAIMS - OZ 50761

3. A compound of the formula I as claimed in claim 1 [either of claims 1 or 2], in which

B can be an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring with a maximum of 15 carbon atoms, an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring with a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms or 0 to 2 sulfur atoms, each of which may also be substituted by a maximum of 3 different or identical R^5 radicals, and one or two carbon or sulfur atoms may also carry one or two =O groups.

6. A compound of the formula I as claimed in claim 1 [either claims 1 or 2], in which

B is L_v-Y-M_w , where

v is 0, and

w is 1, and

Y is a bond, and

M can be a straight-chain or branched carbon chain of 2 to 8 C atoms which contains at least one double bond, it being possible for each carbon atom to be substituted by one or two R^4 radicals and a maximum of two different or identical R^5 radicals, and

R^1 is hydrogen, and


R^4 is $D_{0,1}-F^1_{0,1}-G^1-G^2-G^3$, with G^3 equal to hydrogen, and

D is O and NR^{43} , where R^{43} is hydrogen and C_1 - C_3 -alkyl and

F^1 is C_2 - C_4 -alkyl.

MARKED VERSION OF AMENDED CLAIMS - OZ 50761

7. A drug comprising one or more compounds of the formula I as claimed in claim 1 [any of claims 1 to 6] in addition to conventional carriers and excipients.
8. The use of compounds of the formula I as claimed in claim 1 [any of claims 1 to 6] or of the formula I where R^1 , X^1 and A have the meaning as above, and B can be hydrogen and a C_1 - C_6 -alkyl chain, for producing drugs with a PARP-inhibiting effect.
24. A compound of the formula III



in which

A is a C_1 - C_3 chain it being possible for each carbon atom also to carry one or two of the following substituents: C_1 - C_4 -alkyl, OH, O- C_1 - C_4 -alkyl, CO_2H , $Co_2.C_1$ - C_4 -alkyl and phenyl or one C atom may also carry an =O group, and

X^1 and R^1 have the meanings stated in claim 1 [the previous claims],

excluding the compounds

9-amino-3-methyl-1,2,3,4-tetrahydro-5H-1,4-benzodiazepin-5-one,

9-amino-3-methyl-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione,

MARKED VERSION OF AMENDED CLAIMS - OZ 50761


6,8-diamino-2,4-(1H,3H)-quinazolinedione,

8-amino-2,4-(1H,3H)-quinazolinedione,

and the salts thereof.

CLAIMS AS FILED - OZ 50761

1. A compound of the formula I




in which

- A can be a C₁-C₃ chain where each carbon atom may also carry one or two of the following substituents:
 C₁-C₄-alkyl, OH, O-C₁-C₄-alkyl, COOH, COO-C₁-C₄-alkyl and phenyl or
 one C atom may also carry an =O group, and
- X¹ can be S, O and NH, and
- R¹ is hydrogen, chlorine, fluorine, bromine, iodine, branched and unbranched C₁-C₆-alkyl, OH, nitro CF₃, CN, NR¹¹R¹², NH-CO-R¹³, O-C₁-C₄-alkyl, where R¹¹ and R¹² are, independently of one another, hydrogen, or C₁-C₄-alkyl, and R¹³ is hydrogen, C₁-C₄-alkyl, C₁-C₄-alkyl-phenyl or phenyl, and
- B can be an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring with a maximum of 15 carbon atoms, an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring with a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms or 0 to 2 sulfur atoms, each of which may also be substituted by one R⁴ and a maximum of 3 different or identical R⁵ radicals, and one or two carbon or sulfur atoms may also carry one or two =O groups, or is a radical L_v-Y-M_w in which
- L can be a straight-chain or branched, saturated or unsaturated carbon chain of 1

CLAIMS - OZ 50761

- to 8 C atoms, it being possible for each carbon atom to be substituted by one or two R^4 radicals and a maximum of two different or identical R^5 radicals, and
- M has, independently of L, the same meaning as L, and
- Y is a bond, or can be S, O or NR^3 , where R^3 can be hydrogen, branched and unbranched C_1 - C_6 -alkyl, C_1 - C_4 -alkyl-phenyl, phenyl, and
- v can be 0 and 1, and
- w can be 0 and 1, and
- when Y is a bond, R^4 and R^5 are not both hydrogen, and
- when B is L_v -Y- M_w , R^1 is not chlorine or NO_2 and
- R^4 is hydrogen and $-(D)_p$ -(E)_s-(F¹)_q-G¹-(F²)_r-(G²)-G³, where
- D can be S, NR^{43} and O
- E can be phenyl,




and

- X^4 can be S, O or NH, and
- F^1 can be a straight-chain or branched saturated or unsaturated carbon chain of 1 to 8 C atoms, and
- F^2 has, independently of F^1 , the same meaning as F^1 ,

CLAIMS - OZ 50761

G¹ is a bond or can be an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring with a maximum of 15 carbon atoms, an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring with a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms or 0 to 2 sulfur atoms, each of which may also be substituted by a maximum of 3 different or identical R⁵ radicals, and one or two carbon or sulfur atoms may also carry one or two =O groups, and

G² is NR⁴¹R⁴² and



or a bond, and

G³ can be an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring with a maximum of 15 carbon atoms, an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring with a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms or 0 to 2 sulfur atoms, each of which may also be substituted by a maximum of 3 different or identical radicals R⁵, and one or two carbon or sulfur atoms may also carry one or two =O groups, or is

CLAIMS - OZ 50761

hydrogen, and

p can be 0 and 1 and

s can be 0 and 1 and

q can be 0 and 1 and

r can be 0 and 1 and

R⁴¹ can be hydrogen C₁-C₆-alkyl, it being possible for each carbon atom also to carry up to two R⁶ radicals, phenyl which may also carry a maximum of two R⁶ radicals, and (CH₂)_t-K and

R⁴² can be hydrogen, C₁-C₆-alkyl, -CO-R⁸, CO₂-R⁸, SO₂NH₂, SO₂-R⁸, -(C=NH)-R⁸ and -(C=NH)-NHR⁸ and

R⁴³ can be hydrogen and C₁-C₄-alkyl and

t can be 1, 2, 3, 4 and

K can be NR¹¹R¹², NR¹¹-C₁-C₄-alkyl-phenyl, pyrrolidine, piperidine, 1,2,5,6-tetrahydropyridine, morpholine, homopiperidine, piperazine, which may also be substituted by an alkyl radical C₁-C₆-alkyl, and homopiperazine which may also be substituted by an alkyl radical C₁-C₆-alkyl, and homopiperazine which may also be substituted by an alkyl radical C₁-C₆-alkyl, and

R⁵ can be hydrogen, chlorine, fluorine, bromine, iodine, OH, nitro, CF₃, CN, NR¹¹R¹², NH-CO-R¹³, C₁-C₄-alkyl-CO-NH-R¹³, COR⁸, C₀-C₄-alkyl-O-CO-R¹³, C₁-C₄-alkyl-phenyl, phenyl, CO₂-C₁-C₄-alkyl, and branched and unbranched C₁-C₆-alkyl, O-C₁-C₄-alkyl, S-C₁-C₄-alkyl, it being possible for each C atom of the alkyl

CLAIMS - OZ 50761

chains to carry up to two R^6 radicals, and for the alkyl chains also to be unsaturated, and,

R^6 can be hydrogen, chlorine, fluorine, bromine, iodine, branched and unbranched C_1 - C_6 -alkyl, OH, nitro, CF_3 , CN, $NR^{11}R^{12}$, $NH-CO-R^{13}$, $O-C_1$ - C_4 -alkyl,

R^7 can be hydrogen, C_1 - C_6 -alkyl, phenyl, it being possible for the ring also to be substituted by up to two R^{71} radicals, and an amine $N^{11}R^{12}$ or a cyclic saturated amine which has 3 to 7 members and may also be substituted by an alkyl radical C_1 - C_6 -alkyl, and homopiperazine which may also be substituted by an alkyl radical C_1 - C_6 -alkyl, and homopiperazine which may also be substituted by an alkyl radical C_1 - C_6 -alkyl,

and where the radicals R^{11} , R^{12} and R^{13} in K, R^5 , R^6 and R^7 may, independently of one another, assume the same meaning as for R^1 , and

R^{71} can be OH, C_1 - C_6 -alkyl, $O-C_1$ - C_4 -alkyl, chlorine, bromine, iodine, fluorine, CF_3 , nitro, NH_2 , and

R^8 can be C_1 - C_6 -alkyl, CF_3 , phenyl, C_1 - C_4 -alkyl-phenyl, it being possible for the ring also to be substituted by up to two R^{81} radicals, and

R^{81} can be OH, C_1 - C_6 -alkyl, $O-C_1$ - C_4 -alkyl, chlorine, bromine, iodine, fluorine, CF_3 , nitro NH_2 , and

R^9 can be hydrogen, C_1 - C_6 -alkyl, C_1 - C_4 -alkyl-phenyl, CO_2 - C_1 - C_4 -alkyl-phenyl, CO_2 - C_1 - C_4 -alkyl, SO_2 -phenyl, COR^8 and phenyl, it being possible for the phenyl rings also to be substituted by up to two R^{91} radicals, and

CLAIMS - OZ 50761

R⁹¹ can be OH, C₁-C₆-alkyl, O-C₁-C₄-alkyl, chlorine, bromine, iodine, fluorine, CF₃, nitro, NH₂ and

its tautomeric forms, possible enantiomeric and diastereomeric forms, and prodrugs thereof.

2. A compound of the formula I as claimed in claim 1, where

A is a C₂ chain, which may be substituted, and

X¹ is O, and

R¹ is hydrogen.

3. A compound of the formula I as claimed in claim 1, in which

B can be an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring with a maximum of 15 carbon atoms, an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring with a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms or 0 to 2 sulfur atoms, each of which may also be substituted by a maximum of 3 different or identical R⁵ radicals, and one or two carbon or sulfur atoms may also carry one or two =O groups.

4. A compound of the formula I as claimed in claim 3, where

B is phenyl, cyclohexyl, piperidine, pyridine, pyrimidine, pyrrole, pyrazole, thiophene, furan, oxazole, naphthalene, piperazine, quinoline, pyrazine,

CLAIMS - OZ 50761

each of which may also be substituted by one R^4 or a maximum of 2 R^5 .

5. A compound of the formula I as claimed in claim 4, where

R^4 is hydrogen or $D_{0,1}-F^1_{0,1}-G^2-G^3$ with G^3 equal to hydrogen, and

D is O and NR^{43} , where R^{43} is hydrogen and C_1-C_3 -alkyl and

F^1 is C_2-C_4 -alkyl.

6. A compound of the formula I as claimed in claim 1, in which B is L_v-Y-M_w , where

v is 0, and

w is 1, and

Y is a bond, and

M can be a straight-chain or branched carbon chain of 2 to 8 C atoms which contains at least one double bond, it being possible for each carbon atom to be substituted by one or two R^4 radicals and a maximum of two different or identical R^5 radicals, and

R^1 is hydrogen, and

R^4 is $D_{0,1}-F^1_{0,1}-G^1-G^2-G^3$, with G^3 equal to hydrogen, and

D is O and NR^{43} , where R^{43} is hydrogen and C_1-C_3 -alkyl and

F^1 is C_2-C_4 -alkyl.

7. A drug comprising one or more compounds of the formula I as claimed in claim 1 in addition to conventional carriers and excipients.

8. The use of compounds of the formula I as claimed in claim 1 or of the formula I where R^1 , X^1 and A have the meaning as above, and B can be hydrogen and a


CLAIMS - OZ 50761

- C₁-C₆-alkyl chain, for producing drugs with a PARP-inhibiting effect.
9. The use of compounds of the formula I as claimed in claim 8 for producing drugs for treating neurodegenerative disorders and neuronal damage.
 10. The use as claimed in claim 8 for treating neurodegenerative disorders and neuronal damage caused by ischemia, trauma or massive bleeding.
 11. The use as claimed in claim 8 for treating stroke and craniocerebral trauma.
 12. The use as claimed in claim 8 for treating Alzheimer's disease, Parkinson's disease and Huntington's disease.
 13. The use of compounds of the formula I as claimed in claim 8 for producing drugs for the treatment of prophylaxis of damage due to ischemias.
 14. The use of compound of the formula I as claimed in claim 8 for producing drugs for the treatment of epilepsies, in particular of generalized epileptic seizures, such as, for example, petit mal and tonoclonic seizures and partial epileptic seizures, such as temporal lobe, and complex partial seizures.
 15. The use of compounds of the formula I as claimed in claim 8 for producing drugs for the treatment of damage to the kidneys after renal ischemia, damage caused by drug therapy such as, for example, during cyclosporin therapy, and for treatment during and after kidney transplants.
 16. The use of compounds of the formula I as claimed in claim 8 for producing drugs for the treatment of damage to the heart following cardiac ischemia.
 17. The use of compounds of the formula I as claimed in claim 8 for producing drugs

CLAIMS - OZ 50761

- for the treatment of microinfarcts such as, for example, during and after heart valve replacement, aneurysm resections and heart transplants.
18. The use of compounds of the formula I as claimed in claim 8 for producing drugs for treatment in cases of revascularization of critically narrowed coronary arteries such as, for example in PTCA and bypass operations or of critically narrowed peripheral arteries, especially leg arteries.
 19. The use of compounds of the formula I as claimed in claim 8 for producing drugs for the treatment of acute myocardial infarct and of damage during and after medical or mechanical lysis thereof.
 20. The use of compounds of the formula I as claimed in claim 8 for producing drugs for the treatment of tumors and metastasis thereof.
 21. The use of compounds of the formula I as claimed in claim 8 for producing drugs for the treatment of sepsis, of multiorgan failure such as, for example, during septic shock and of acute respiratory distress syndrome.
 22. The use of compounds of the formula I as claimed in claim 8 for producing drugs for the treatment of immunological disorders such as inflammations and rheumatic disorders such as, for example, rheumatoid arthritis.
 23. The use of compounds of the formula I as claimed in claim 8 for producing drugs for the treatment of diabetes mellitus.
 24. A compound of the formula III

CLAIMS - OZ 50761



III

in which

A is a C₁-C₃ chain it being possible for each carbon atom also to carry one or two of the following substituents: C₁-C₄-alkyl, OH, O-C₁-C₄-alkyl, CO₂H, Co₂-C₁-C₄-alkyl and phenyl or one C atom may also carry an =O group, and

X¹ and R¹ have the meanings stated in claim 1,

excluding the compounds

9-amino-3-methyl-1,2,3,4-tetrahydro-5H-1,4-benzodiazepin-5-one,

9-amino-3-methyl-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione,

6,8-diamino-2,4-(1H,3H)-quinazolinedione,

8-amino-2,4-(1H,3H)-quinazolinedione,

and the salts thereof.

25. A process for preparing compounds of the formula III and salts thereof, wherein 2-halo-3-nitrobenzoic esters are reacted with a suitable diamine in a polar solvent in the presence of a base, and then the nitro group is hydrogenated with hydrogen in the presence of a suitable catalyst.

26. The use of compounds of the formula III in the synthesis of PARP inhibitors.